Ra Pharmaceuticals (RARX) Prices Larger Common Stock IPO at $13/Share, in Middle of Expected Range
- Donald Trump Sworn in as 45th U.S. President
- Wall Street ends higher as Trump becomes president
- Walgreens Boots Alliance (WBA) Said to Face Antitrust Concern for Rite Aid (RAD) Fix - Bloomberg
- Bristol-Myers Squibb (BMY) Says It Won't Pursue Accelerated U.S. Regulatory Pathway for Opdivo Plus Yervoy in Lung Cancer
- Apple (AAPL) Sues Qualcomm (QCOM) Over Patent Royalties in Antitrust Case - Bloomberg
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Ra Pharmaceuticals, Inc. (Nasdaq: RARX), a clinical stage biopharmaceutical company focusing on using its proprietary peptide chemistry platform to develop novel therapeutics for the treatment of serious diseases that are caused by excessive or uncontrolled activation of the complement system, a critical component of the immune system, announced the pricing of its initial public offering of 7,049,230 shares of common stock at a public offering price of $13.00 per share. In addition, Ra has granted the underwriters a 30-day option to purchase up to 1,057,385 additional shares of common stock at the initial public offering price, less the underwriting discount. Ra’s common stock is expected to begin trading on the NASDAQ Global Market under the ticker symbol "RARX" on October 26, 2016.
(NOTE: The company was recently looking for a pricing range of $12 to $14 per share, but was planning to offer only 5.8 million shares.)
Credit Suisse Securities (USA) LLC, Jefferies LLC, and BMO Capital Markets Corp. are acting as joint book-running managers for the offering. SunTrust Robinson Humphrey is acting as lead manager.
A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on October 25, 2016. The offering will be made only by means of a prospectus. Copies of the final prospectus related to the offering may be obtained, when available, from: Credit Suisse Securities (USA) LLC, Attn: Prospectus Dept., One Madison Avenue, New York, NY 10010, by telephone at 800- 221-1037 or by email at firstname.lastname@example.org; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-547-6340 or by email at Prospectus_Department@Jefferies.com; or BMO Capital Markets Corp., Attention: Equity Syndicate Department, 3 Times Square, New York, NY 10036, telephone: (800) 414-3627, email: email@example.com.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Herbalife (HLF) Provides Q4, FY17 Guidance in Memorandum for $1.325B Credit Facility; Lowers FY17 Sales Guidance
- Keane Group (FRAC) IPO Opens Up 16%
- Amaya (AYA) Sees Higher 2016 Revs, EBITDA, EPS; CFO Daniel Sebag to Retire
Create E-mail Alert Related CategoriesCorporate News, Hot Corp. News, IPOs
Related EntitiesCredit Suisse, Jefferies & Co, BMO Capital, SunTrust Robinson Humphrey, IPO
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!